Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

TCA 650 therapy in the phase 2 trial was administered for the 90-day treatment period with a single insertion of ITCA 650 on day 1 and removal on or about day 90. The extension phase of the 2 trial evaluated higher doses of ITCA 650 using a single device to deliver 3 months of treatment. The phase 3 study planned for 2011 will evaluate treatment regimens involving initial 12-week ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day thereafter using ITCA 650 devices of both 6- and 12-month duration.

A downloadable version of the ITCA 650 phase 2 presentation from ADA is available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2 diabetes consists of DUROS continuous subcutaneous delivery of exenatide. Intarcia's delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

A single DUROS device can deliver up to a full year of ITCA 650 therapy. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy, if required. ITCA 650 is an investigational new drug and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Type 2 DiabetesAccording to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 o
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and ... a new genetic test built upon research from their ... will provide physicians with an objective way to ... are stratified between individuals. With this new test, physicians ... a genetic predisposition that will affect their pain tolerance. ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
Breaking Biology Technology:Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... to lead ... expansion, FORT WORTH, ... today the appointment of,Michael J. "Mike" Tansey as Chief Executive Officer., ... is poised to,enter a period of accelerated growth," said Mr. Tansey. "The ...
... Chatterjee Brings Over Thirteen Years of Capital Markets ... Experience to AOBO -,- New Role Emphasizes Strategic Growth Plan and Capital ... ... Inc. (NYSE: AOB ) ("AOB" or "the Company"), a pharmaceutical,company dedicated to improving health ...
... a Hearing -, MONTVALE, N.J., June 9 ... on June 6, 2008 it received a,letter from the ... has not regained compliance with the $1.00 bid,price requirement ... to delisting from The NASDAQ Global Market, unless the ...
Cached Biology Technology:onTargetjobs Announces Appointment of Michael Tansey as New CEO 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 2Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 3
(Date:9/30/2014)... release is available in German . ... among the most expensive foods in the world. Because they ... them. But the distinctive smell of truffles is not only ... scientists under the direction of the Goethe University Frankfurt have ... by soil bacteria which are trapped inside truffle fruiting bodies. ...
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... over global warming and instead reduce fossil-fuel use for the ... scientists, one from the University of Washington and one from ... in the current issue of the journal Nature ... supply will trump the environment as a reason to curb ...
... Irvine, Calif., Jan. 26, 2012 Location matters for ... UC Irvine and Wesleyan University. Findings suggest that chickadees and ... as the characteristics of their wriggly prey. Unfortunately for ... can dramatically boost their own risk of becoming food. Study ...
... for breast cancer research as well as basic cell ... Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered a ... ability of breast cells to form the spherical structures ... which the researchers call "CAMo," for coherent angular motion, ...
Cached Biology News:Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3For the birds 2Berkeley Lab researchers discover critical rotational motion in cells 2Berkeley Lab researchers discover critical rotational motion in cells 3Berkeley Lab researchers discover critical rotational motion in cells 4
... lyophilization stabilizer is designed to stabilize ... for long-term storage. There are ... It is a convenient 10 ... and is superior to other traditional ...
... Techne TC-512 is the only Gradient thermal cycler ... the touch of a screen. ,Wide linear ... the market, with an amazing range of,30C. Protocols ... , TouchScreen - The Touchgene Gradient incorporates a ...
... The Freedom EVO Clinical is Tecans open ... to enhance quality, safety and performance in ... Safety is provided by flexible barcode reading ... to mention that the system complies with ...
Request Info...
Biology Products: